JP2011519833A5 - - Google Patents

Download PDF

Info

Publication number
JP2011519833A5
JP2011519833A5 JP2011505616A JP2011505616A JP2011519833A5 JP 2011519833 A5 JP2011519833 A5 JP 2011519833A5 JP 2011505616 A JP2011505616 A JP 2011505616A JP 2011505616 A JP2011505616 A JP 2011505616A JP 2011519833 A5 JP2011519833 A5 JP 2011519833A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
peg
fix
composition according
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011505616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519833A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2009/005763 external-priority patent/WO2009130602A2/en
Publication of JP2011519833A publication Critical patent/JP2011519833A/ja
Publication of JP2011519833A5 publication Critical patent/JP2011519833A5/ja
Pending legal-status Critical Current

Links

JP2011505616A 2008-04-24 2009-04-24 半減期が延長された第ix因子コンジュゲート Pending JP2011519833A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4754408P 2008-04-24 2008-04-24
US61/047,544 2008-04-24
PCT/IB2009/005763 WO2009130602A2 (en) 2008-04-24 2009-04-24 Factor ix conjugates with extended half-lives

Publications (2)

Publication Number Publication Date
JP2011519833A JP2011519833A (ja) 2011-07-14
JP2011519833A5 true JP2011519833A5 (enExample) 2012-06-14

Family

ID=41171051

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505616A Pending JP2011519833A (ja) 2008-04-24 2009-04-24 半減期が延長された第ix因子コンジュゲート

Country Status (22)

Country Link
US (1) US20110183906A1 (enExample)
EP (1) EP2280734B1 (enExample)
JP (1) JP2011519833A (enExample)
KR (1) KR20110016440A (enExample)
CN (1) CN102046205A (enExample)
AU (1) AU2009239641B2 (enExample)
BR (1) BRPI0911350A2 (enExample)
CA (1) CA2722169A1 (enExample)
CO (1) CO6300965A2 (enExample)
CR (1) CR11763A (enExample)
DK (1) DK2280734T3 (enExample)
EC (1) ECSP10010632A (enExample)
ES (1) ES2466340T3 (enExample)
IL (1) IL208908A0 (enExample)
MX (1) MX2010011672A (enExample)
MY (1) MY158228A (enExample)
NI (1) NI201000177A (enExample)
NZ (1) NZ588854A (enExample)
RU (1) RU2496521C2 (enExample)
UA (1) UA101497C2 (enExample)
WO (1) WO2009130602A2 (enExample)
ZA (1) ZA201007559B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
RU2595442C2 (ru) 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP6250282B2 (ja) * 2009-08-20 2017-12-20 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
ES3050283T3 (en) * 2010-07-09 2025-12-19 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
CA2836478A1 (en) * 2011-05-27 2012-12-06 Baxter International Inc. Therapeutic protein conjugated to water-soluble polymers via reduced cysteine sulfhydryl group
AP2014008049A0 (en) 2012-04-16 2014-11-30 Cantab Biopharmaceuticals Patents Ltd Optimised subcuraneous therapeutic agents
RU2015101333A (ru) * 2012-06-19 2016-08-10 Политерикс Лимитед Новый способ получения конъюгатов антител и новые конъюгаты антител
EP3542861A1 (en) 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
GB2564389A (en) 2017-07-04 2019-01-16 Green Running Ltd A system and method for utility management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
KR101025143B1 (ko) * 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드-종결 중합체
WO2004060966A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Maleamic acid polymer derivatives and their bioconjugates
MXPA05007348A (es) * 2003-01-06 2005-10-05 Nektar Therapeutics Al Corp Derivados de polimeros solubles en agua tiol-selectivos.
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ATE455174T1 (de) 2003-09-23 2010-01-15 Univ North Carolina Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ix因子調製物およびその精製方法
PL2189523T3 (pl) 2003-10-14 2012-05-31 Baxalta Inc Polipeptyd przekształcający epoksyd witaminy K VKORC1, obiekt działania leczniczego kumaryny i jej pochodnych
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2005260763B2 (en) * 2004-06-30 2011-12-22 Nektar Therapeutics Polymer-factor IX moiety conjugates
WO2006063292A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
CN103396998A (zh) 2005-02-28 2013-11-20 巴克斯特国际公司 重组共表达维生素k环氧化物还原酶亚基1以提高依赖维生素k的蛋白质表达
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
JP2009532351A (ja) * 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第viii因子
RU2008145084A (ru) * 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病b治療剤及びその製造方法

Similar Documents

Publication Publication Date Title
JP2011519833A5 (enExample)
JP2013525414A5 (enExample)
RU2010147813A (ru) Конъюгаты фактора ix с увеличенным временем полужизни
CA2796870A1 (en) Conjugated blood coagulation factor viia
RU2012144555A (ru) Конъюгированный фактор свертывания крови viii
US12214044B2 (en) Factor VIII zwitterionic polymer conjugates
JP7014844B2 (ja) オキシム連結のための求核触媒
JP2013511540A5 (enExample)
JP2014040441A5 (enExample)
JP2008542285A5 (enExample)
Hu et al. In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms PEGASYS in cancer therapy
JP6004449B2 (ja) トリブロックコポリマー及びその使用
RU2447083C1 (ru) НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
JP7046321B2 (ja) 修飾されたスチレン-無水マレイン酸共重合体及びその使用
JP2011507913A5 (enExample)
JP2014525939A (ja) ペグインターフェロンλ1複合体
JP6253008B2 (ja) 高分子化ホウ素化合物及びその使用
CN102153643B (zh) 粒细胞集落形成刺激因子(g-csf)的突变体及其化学缀合多肽
JP5363987B2 (ja) ポリエチレングリコール−g−csf結合体
US20170079928A1 (en) Copolymers of formula (i) and uses
RU2597795C2 (ru) Ингибитор скопления жидкости в полостях организма
WO2021124266A1 (en) Pegylation of a trail ligand
HK40043414A (en) Zwitterionic polymer conjugates
HK40043412A (en) Zwitterionic polymer conjugates
TW202302149A (zh) 硫代琥珀醯交聯之血紅素共軛物及其使用與製備方法